Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: Implications for tumor metastasis

Glycobiology

Volumn 20, Issue 11, 2010, Pages 1341-1352

  De Oliveira, Joana Tavares ^a   De Matos, Augusto J F ^a   Gomes, Joana ^a   Vilanova, Manuel ^a   Hespanhol, Venceslau ^b   Manninen, Aki ^c   Rutteman, Gerard ^d   Chammas, Roger ^e   Grtner, Ftima ^a   Bernardes, Emerson Soares ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF OULU   (Finland)

^d UTRECHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

extracellular matrix; galectin 3; galectin 3 binding sites; metastasis; tumor stroma

Indexed keywords

BINDING PROTEIN; COLLAGEN; GALECTIN 1; GALECTIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CELL SUBPOPULATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BINDING SITES; CELL TRANSFORMATION, NEOPLASTIC; DOGS; DOWN-REGULATION; FEMALE; GALECTIN 3; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM METASTASIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77957843649     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwq103     Document Type: Article

References (50)

1. Ahmed H, Allen HJ, DiCioccio RA. 1991. Binding of hydroxylysine-linked saccharides by galaptin, agalactoside-binding animal tissue lectin. Carbohydr Res. 213:321-324.
2. Bockhorn M, Jain RK, Munn LL. 2007. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol. 8:444-448.
3. Califice S, Castronovo V, Bracke M, van den Brûle F. 2004. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene. 23:7527-7536.
4. Castronovo V, Van Den Brûle FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME. 1996. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 179:43-48. (Pubitemid 26182865)
5. Chambers AF, Groom AC, MacDonald IC. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563-572.
6. Choi YK, Hong SH, Kim BH, Kim HC, Woo HJ, Kim DY. 2004. Immunohis-tochemical expression of galectin-3 in canine mammary tumours. J Comp Pathol. 131:242-245.
7. Choufani G, Nagy N, Saussez S, et al. 1999. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 86:2353-2363.
8. de Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Dos Santos MS, Rutteman GR, Gärtner M de F. 2006. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. Anticancer Res. 26:1821-1826.
9. de Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Rutteman GR, Gärtner M de F. 2007. E-cadherin, beta-catenin, invasion and lymph node metastases in canine malignant mammary tumours. APMIS. 115:327-334.
10. de Melo FH, Butera D, Medeiros RS, Andrade LN, Nonogaki S, Soares FA, Alvarez RA, Moura da Silva AM, Chammas R. 2007. Biological applications of a chimeric probe for the assessment of galectin-3 ligands. J Histochem Cytochem. 55:1015-1026.
11. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. 1999. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 27:362-367.
12. Friedrichs J, Torkko JM, Helenius J, Teravainen TP, Fullekrug J, Muller DJ, Simons K, Manninen A. 2007. Contributions of galectin-3 and -9 to epithelial cell adhesion analysed by single cell force spectroscopy. J Biol Chem. 282:29375-29383.
13. Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE. 2010. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol. 4(1): 65-89.
14. Hellmén E. 1992. Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines. In Vitro Cell Dev Biol. 28:309-319.
15. Ho MK, Springer TA. 1982. Mac-2, a novel 32, 000 Mr mouse macrophage subpopulation-specific antigen definedby monoclonal antibodies. J Immunol. 128:1221-1228.
16. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kubo T. 2000. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 6:4635-4640.
17. Honjo Y, Nangia-Makker P, Inohara H, Raz A. 2001. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 7:661-668.
18. Hughes RC. 2001. Galectins as modulators of cell adhesion. Biochimie. 83:667-676.
19. Inohara H, Akahani S, Koths K, Raz A. 1996. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 56:4530-4534.
20. Jung EJ, Moon HG, Cho BI, et al. 2007. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer. 120(11): 2331-2338.
21. Kim HR, Lin HM, Biliran H, Raz A. 1999. Cell cycle arrest and inhibition of an-oikisbygalectin-3 in human breast epithelial cells. Cancer Res. 59:4148-4154.
22. Kuwabara I, Liu FT. 1996. Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol. 156:3939-3944.
23. Lauer-Fields JL, Malkar NB, Richet G, Drauz K, Fields GB. 2003. Melanoma cell CD44 interaction with the alpha 1(IV) 1263-1277 region from basement membrane collagen is modulated by ligand glycosylation. J Biol Chem. 278:14321-14330.
24. Lin HM, Pestell RG, Raz A, Kim HR. 2002. Galectin-3 enhances cyclin D (1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene. 21:8001-8010.
25. Liotta LA, Kohn EC. 2001. The microenvironment of the tumour-host interface. Nature. 411:375-379.
26. Liu FT, Rabinovich GA. 2005. Galectins as modulators of tumour progression. Nat Rev Cancer. 5:29-41.
27. Lotz MM, Andrews CWJr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A, Mercurio AM. 1993. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA. 90: 3466-3470.
28. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 156:899-909.
29. Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A. 2007. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res. 67:11760-11768.
30. Nangia-Makker P, Balan V, Raz A. 2008. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviroǹ. 1:43-51.
31. Neder L, Marie SK, Carlotti CG Jr, et al. 2004. Galectin-3 as an immuno-histochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol. 14:399-405.
32. Nollet F, Berx G, van Roy F. 1999. The role of the E-Cadherin/Catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun. 2(2): 77-85.
33. Ochieng J, Leite-Browning ML, Warfield P. 1998. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 29(246): 788-791.
34. Ochieng J, Warfield P, Green-Jarvis B, Fentie I. 1999. Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J Cell Biochem. 75:505-514.
35. Ochieng J, Furtak V, Lukyanov P. 2004. Extracellular functions of galectin-3. Glycoconj J. 19:527-535.
36. Orr FW, Wang HH. 2001. Tumor cell interactions with the microvasculature: a rate-limiting step in metastasis. Surg Oncol Clin N Am. 10:357-381.
37. Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR. 2000. Decreased galectin-3 expression in prostate cancer. Prostate. 44:118-123.
38. Paoloni M, Khanna C. 2008. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 8:147-156.
39. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. 1998. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 392: 190-193.
40. Pinho SS, Osório H, Nita-Lazar M, Gomes J, Lopes C, Gärtner F, Reis CA. 2009. Role of E-cadherin N-glycosylation profile in a mammary tumour model. Biochem Biophys Res Commun. 379:1091-1096.
41. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. 1998. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 95:4589-4594.
42. Sanjuán X, Fernández PL, Castells A, Castronovo V, van den Brûle F, Liu FT, Cardesa A, Campo E. 1997. Differential expression of galectin 3 and galec-tin 1 in colorectal cancer progression. Gastroenterology. 113:1906-1915.
43. Schegg B, Hülsmeier AJ, Rutschmann C, Maag C, Hennet T. 2009. Core gly-cosylation of collagen is initiated by two beta (1-O) galactosyltransferases. Mol Cell Biol. 29:943-952.
44. Sorenmo K. 2003. Canine mammary gland tumors. Vet Clin N Am Small Anim Pract. 33:573-596.
45. Swartz MA, Kristensen CA, Melder RJ, Roberge S, Calautti E, Fukumura D, Jain RK. 1999. Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br J Cancer. 81: 756-759.
46. Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell. 139(5): 871-890.
47. van den Brûle FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V. 1994. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 30:1096-1099.
48. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. 2007. Direct visualizationof macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 67:2649-2656.
49. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. 2002. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 277:6852-6857.
50. Zhuo Y, Chammas R, Bellis SL. 2008. Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. J Biol Chem. 283:22177-22185.